Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- MYCOPHENOLATE-MOFETIL;; INTRAVENOUS CYCLOPHOSPHAMIDE;; RHEUMATOID-ARTHRITIS;; ERYTHEMATOSUS SLE;; RANDOMIZED-TRIAL;; MURINE LUPUS;; THERAPY;; GLOMERULONEPHRITIS;; CLASSIFICATION;; COSTIMULATION;; Rheumatology (1)
- NUTRITION EXAMINATION SURVEY;; VITAMIN-D DEFICIENCY;; CALCIUM/VITAMIN-D;; SUPPLEMENTATION;; CORONARY-ARTERY CALCIFICATION;; RENIN-ANGIOTENSIN;; SYSTEM;; 3RD NATIONAL-HEALTH;; RISK-FACTORS;; ACCELERATED ATHEROSCLEROSIS;; PREMATURE ATHEROSCLEROSIS;; MYOCARDIAL-INFARCTION;; Rheumatology (1)
Articles 1 - 4 of 4
Full-Text Articles in Allergy and Immunology
Noninfectious Manifestations And Complications Of Chronic Granulomatous Disease, S. E. Henrickson, A. M. Jongco, K. F. Thomsen, E. K. Garabedian, I. P. Thomsen
Noninfectious Manifestations And Complications Of Chronic Granulomatous Disease, S. E. Henrickson, A. M. Jongco, K. F. Thomsen, E. K. Garabedian, I. P. Thomsen
Journal Articles
© The Author(s) 2018. Chronic granulomatous disease (CGD), a primary immunodeficiency characterized by a deficient neutrophil oxidative burst and the inadequate killing of microbes, is well known to cause a significantly increased risk of invasive infection. However, infectious complications are not the sole manifestations of CGD; substantial additional morbidity is driven by noninfectious complications also. These complications can include, for example, a wide range of inflammatory diseases that affect the gastrointestinal tract, lung, skin, and genitourinary tract and overt autoimmune disease. These diseases can occur at any age and are especially problematic in adolescents and adults with CGD. Many of …
Considerations In The Diagnosis Of Chronic Granulomatous Disease, J. E. Yu, A. E. Azar, H. J. Chong, A. M. Jongco, B. T. Prince
Considerations In The Diagnosis Of Chronic Granulomatous Disease, J. E. Yu, A. E. Azar, H. J. Chong, A. M. Jongco, B. T. Prince
Journal Articles
© The Author(s) 2018. Chronic granulomatous disease (CGD) is a rare primary immunodeficiency that is caused by defects in the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex. The disease presents in most patients initially with infection, especially of the lymph nodes, lung, liver, bone, and skin. Patients with CGD are susceptible to a narrow spectrum of pathogens, and Staphylococcus aureus, Burkholderia cepacia complex, Serratia marcescens, Nocardia species, and Aspergillus species are the most common organisms implicated in North America. Granuloma formation, most frequently in the gastrointestinal and genitourinary systems, is a common complication of CGD and can be seen even …
Treatment Of Lupus Nephritis With Abatacept, A. D. Askanase, M. Byron, L. L. Keyes-Elstein, P. C. Cagnoli, W. J. Mccune, W. W. Chatham, A. Davidson, B. Diamond, M. Mackay, R. Winchester, +24 Additional Authors
Treatment Of Lupus Nephritis With Abatacept, A. D. Askanase, M. Byron, L. L. Keyes-Elstein, P. C. Cagnoli, W. J. Mccune, W. W. Chatham, A. Davidson, B. Diamond, M. Mackay, R. Winchester, +24 Additional Authors
Journal Articles
Objective. To assess the efficacy and safety of a 24-week course of abatacept in the treatment of active lupus nephritis and to assess the potential of abatacept to induce "clinical tolerance," defined as sustained clinical quiescence of lupus nephritis after discontinuation of immunosuppressive therapy. Methods. Patients with active lupus nephritis (n = 134) were enrolled in a randomized, double-blind phase II add-on trial in which they received either abatacept or placebo in conjunction with the Euro-Lupus Nephritis Trial regimen of low-dose cyclophosphamide (CYC) followed by azathioprine (AZA). The primary efficacy outcome was the frequency of complete response at week 24. …
25-Hydroxyvitamin D And Cardiovascular Disease In Patients With Systemic Lupus Erythematosus: Data From A Large International Inception Cohort, A. Lertratanakul, P. Wu, A. Dyer, M. Urowitz, D. Gladman, C. Aranow, J. Font, R. Van Vollenhoven, T. Stoll, R. Ramsey-Goldman, +20 Additional Authors
25-Hydroxyvitamin D And Cardiovascular Disease In Patients With Systemic Lupus Erythematosus: Data From A Large International Inception Cohort, A. Lertratanakul, P. Wu, A. Dyer, M. Urowitz, D. Gladman, C. Aranow, J. Font, R. Van Vollenhoven, T. Stoll, R. Ramsey-Goldman, +20 Additional Authors
Journal Articles
Objective. An association between 25-hydroxyvitamin D (25[ OH] D; vitamin D) deficiency and increased cardiovascular (CV) risk factors and CV disease (CVD) has been shown in general population studies. Vitamin D deficiency has been noted in systemic lupus erythematosus (SLE), and CVD is a major cause of morbidity and mortality in SLE. The objectives of this study were to estimate the associations of 25(OH) D levels with CV risk factors and to determine whether low baseline 25(OH) D levels predict future CV events in patients participating in an international inception cohort. Methods. Data were collected on 890 participants, including demographics, …